Licensing is a key component of Nycomeds strategy on a global as well as on a regional and local level – all to support the continued growth of Nycomed and brace the company’s position as one of the global top 30 pharmaceutical companies.

Hence in-licensing, partnerships, strategic alliances and good vendor relationships are essential to Nycomed in all phases of a product lifecycle in order to bring the best opportunities into action – carefully adapted the local conditions where Nycomed operates, to optimise the return and mutual benefit of all involved parties.

We offer our partners a platform of direct access into the markets where Nycomed is one of the major influential pharmaceutical companies and important stakeholders in the local communities.

To any future partner we offer;

• Access to a fully developed marketing and sales organisation throughout the agreed territory ready to contribute and deliver extraordinary results on and new opportunities to your property
• Knowledgeable and experienced regulatory capabilities dedicated to local portfolios and authorities ensuring fastest possible regulatory handing.
• Dedicated local medical advicers securing a a precious scientific positioning and smooth market entry within the frames of current regulations.
• A vast development and project organisation carrying all relevant subjects to support and secure a smooth entrance into the agreed territories.
• An organisation and a mindset committed to partnering and strategic alliances – we envision the preferred partner
• A mature and proven track record of partnering capabilities

We are seeking products within the therapeutical areas:

• Pain (nociceptive and neuropathic)
• Gastroenterology (treatment of gastric ulcer and reflux, TNF's, inflammatory bowel disorders)
• Respiratory (COPD, astma, potent antibiotics for hospital acquired pneumonias and LRTI's)
• Cardiology (focus on NCE's for hypertension)
• CNS (Alzheimer disease, depression, anxiety, Parkinson disease, schizophrenia)
• Osteoporosis
• Metabolism (Type 2 diabetes)
• Tissue sealing (focus on hospital settings)
• Haemostasis
• Oncology (small and non-small lung cancer; prostate cancer; treatment support – anti-emetics, CSF)
• Hospital solutions (niche products, unmet medical needs)

We are further seeking self care drugs or medical device status products with the therapeutical areas:

• Allergy
• Cough and Cold products (e.g. nasal applications, throath preparations, systemic products against common cold, anti)
• Vitamins and Minerals
• Laxatives
• Diarrhea (biological preparations/probiotics, preparations preventing bowel motility)
• Oral health (dental-/mouth-preparations)

Our focus on in-licensing partneship lies on late development phase ( phase III ) or ready to be marketed New Chemical Entity (NCE) products, which have clear value added features and USP improving the treatment outcome from existing therapies. Moreover we have selected interest towards generic products, with commercial potential locally. The licensing opportunity should be provided with an adequate CDT-format registration dossier.